Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORAVESCENT Fentanyl for Breakthrough Pain in Chronic Low Back Pain
NCT00214942Phase 3Completed
- Sponsor
- Cephalon, Inc.
- Start
- Sep 2005
- Primary completion
- Mar 2006
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breakthrough pain comparing ORAVESCENT Fentanyl with Placebo (2 arms). Primary endpoint: Sum of Pain Intensity Differences at 30 Minutes. Started Sep 2005; status: completed.
02
Drugs
fentanyl
03
Conditions
breakthrough pain
Beyond the preview
Go deeper on NCT00214942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00214942.